Pharmaceutical

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Retrieved on: 
Monday, May 16, 2022 - 6:30am

The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.

Key Points: 
  • The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.
  • The launch of QIAstat-Dx Rise syndromic testing platform provides automated, comprehensive pathogen testing for higher-demand medical institutions, said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN.
  • QIAstat-Dx Rise and its test cartridges are a closed system for hands-off sample preparation and processing.
  • Building on the existing QIAstat-Dx Analyzer with up to four analytical modules, QIAstat-Dx Rise is a flexible new option for increased testing capacity.

Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5

Retrieved on: 
Monday, May 16, 2022 - 7:00am

ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.

Key Points: 
  • ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.
  • Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

Retrieved on: 
Sunday, May 15, 2022 - 6:24pm

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • AstraZenecas ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
  • Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
  • The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK.

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

Retrieved on: 
Sunday, May 15, 2022 - 7:15pm

Patients with PCD have a high burden of morbidity with chronic respiratory infections, bronchiectasis, and often develop respiratory failure.

Key Points: 
  • Patients with PCD have a high burden of morbidity with chronic respiratory infections, bronchiectasis, and often develop respiratory failure.
  • ReCode is developing a disease-modifying mRNA-based approach for the treatment of PCD caused by mutations in DNAI1, an essential gene for ciliary movement.
  • Full details from the data presented at ATS 2022 can be accessed via the Publications section on ReCodes website.
  • ReCode will also present new preclinical data from its mRNA-based therapeutic program for cystic fibrosis on Wednesday, May 18th.

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Retrieved on: 
Sunday, May 15, 2022 - 5:41pm

In patients already taking antifibrotic therapy, the median changes in FVC were +2.7 mL for BI 1015550 and -59.2 mL in the placebo arm.

Key Points: 
  • In patients already taking antifibrotic therapy, the median changes in FVC were +2.7 mL for BI 1015550 and -59.2 mL in the placebo arm.
  • There is >98% probability that BI 1015550 was superior to placebo in slowing down the worsening of lung function in people with IPF.
  • The Phase II results reinforce our confidence in BI 1015550 which will be accelerated into a pivotal Phase III program.
  • We will work with regulatory agencies and scientific communities to potentially bring the next generation of treatments to people living with pulmonary fibrosis as quickly as possible.

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

Retrieved on: 
Sunday, May 15, 2022 - 3:05pm

Two podium presentations at AUA2022 on May 15 featured new analyses of data from the EMPOWUR 40-week extension trial of GEMTESA (vibegron) 75 mg.

Key Points: 
  • Two podium presentations at AUA2022 on May 15 featured new analyses of data from the EMPOWUR 40-week extension trial of GEMTESA (vibegron) 75 mg.
  • In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA was safe and well tolerated.
  • Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition, UUI episodes, and urgency episodes.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Buxton Helmsley Issues Letter to Endo International Plc. Shareholders and Creditors, Relating to Corporate Malfeasance and False Statements of Financials

Retrieved on: 
Friday, May 13, 2022 - 9:10pm

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, BHG or we), the New York City-based investment advisor to clients with financial interests in Endo International Plc.

Key Points: 
  • The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, BHG or we), the New York City-based investment advisor to clients with financial interests in Endo International Plc.
  • (Endo or the Company) (NASDAQ: ENDP), today issued an open letter to shareholders and creditors of the Company, relating to corporate malfeasance and false statements of financial position.
  • The full open letter to the Companys shareholders and creditors, along with the private letters between BHG and the Company leading up to this open letter, may be found at: http://www.exposingendo.com/
    Members of the Endo International Plc.
  • About Buxton Helmsley: The Buxton Helmsley Group, Inc. ("BHG") is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts and other entities.

Soleo Health Earns Five Stevie® Awards in 2022 American Business Awards®

Retrieved on: 
Friday, May 13, 2022 - 7:27pm

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it was named the winner of four Gold Stevie Awards and one Silver in The 20th Annual American Business Awards (ABA).

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it was named the winner of four Gold Stevie Awards and one Silver in The 20th Annual American Business Awards (ABA).
  • Additionally, Soleo Health earned Gold for Company of the Year - Health Products & Services - Large companies.
  • We are honored to be recognized by the American Business Awards and bestowed five Stevie Awards.
  • Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service.

Huntington Medical Research Institutes Present First-of-its-Kind Study Examining Impact of Erectile Dysfunction Drugs on Major Adverse Cardiovascular Events and Mortality

Retrieved on: 
Friday, May 13, 2022 - 7:01pm

Scientists from Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California San Francisco analyzed health records of more than 70,000 men with ED.

Key Points: 
  • Scientists from Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California San Francisco analyzed health records of more than 70,000 men with ED.
  • They compared rates of major adverse cardiovascular events (MACE) and death amongst men who took phosphodiesterase type 5 inhibitor (PDE-5i) drugsincluding Viagra, Cialis and Levitrato rates among men who never took these drugs.
  • Since the study was retrospective, Kloner noted that further research is needed to prove that PDE-5i drugs caused the reduction in cardiovascular events that he and his co-investigators observed.
  • Huntington Medical Research Institutes (HMRI) works to improve millions of lives through patient-focused scientific research.